Finally, we demonstrate that uptake of the mAb into cancer cells results in inhibition of KRAS signalling, in vitro, suggesting that an antibody-based approach to target the fully open state of G13D is a compelling and exciting possibility for future therapeutics. This evidence concerns the gene KRAS and cancer.